Cargando…
One-Year Outcomes of 1 Dose versus 3 Loading Doses Followed by Pro Re Nata Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration: The ARTIS Trial
Purpose. To compare the functional and anatomical outcomes of one dose and three loading doses followed by the pro re nata (PRN) regimen in Chinese neovascular age-related macular degeneration (nvAMD) (including polypoidal choroidal vasculopathy (PCV)) patients. Methods. In this multicenter, prospec...
Autores principales: | Wang, Fenghua, Yuan, Yuanzhi, Wang, Ling, Ye, Xiaofeng, Zhao, Jingke, Shen, Mengxi, Zhang, Qi, Xu, Ding, Qin, Guoyou, Zhang, Wei, Yuan, Fei, Chang, Qing, Zhao, Peiquan, Wang, Fang, Sun, Xiaodong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811781/ https://www.ncbi.nlm.nih.gov/pubmed/31687203 http://dx.doi.org/10.1155/2019/7530458 |
Ejemplares similares
-
A Randomized, Controlled Trial of Treat-and-Extend vs. Pro Re Nata Regimen for Neovascular Age-Related Macular Degeneration
por: Jia, Huixun, et al.
Publicado: (2022) -
Efficacy and safety of Pro Re Nata regimen without loading dose ranibizumab injections in retinal vein occlusion
por: Unsal, Erkan, et al.
Publicado: (2015) -
Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab
por: Elwes, Flora, et al.
Publicado: (2018) -
Intravitreal injection of ranibizumab using a pro re nata regimen for age-related macular degeneration and vision-related quality of life
por: Inoue, Maiko, et al.
Publicado: (2014) -
Treat-and-Extend vs. Pro Re Nata Regimen of Ranibizumab for Diabetic Macular Edema—A Two-Year Matched Comparative Study
por: Lai, Tso-Ting, et al.
Publicado: (2022)